SCHEMBL30296293

SCHEMBL30296293

C=CCC[C@@H](Nc1ccc(OC)cc1)c1c(OC)cnc(F)c1Cl

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
AURKA O14965 2/20 0.33
SYK P43405 1/20 0.33
EGFR P00533 1/20 0.32
GAA P10253 2/20 0.32
BCL6 P41182 2/20 0.31
FGFR1 P11362 1/20 0.31
FGFR2 P21802 1/20 0.31
FGFR4 P22455 1/20 0.31
FGFR3 P22607 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30296339 0.89 ALDH1A1 (0.42) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL26880444 0.83 MEN1 (0.36) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL30391323 0.83 MEN1 (0.36) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL26095417 0.82 SMN1; SMN2 (0.35) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL26095368 0.82 MAPT (0.34) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL30296690 0.82 MAPT (0.34) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL26095414 0.82 SMN1; SMN2 (0.35) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL26095370 0.82 MAPT (0.34) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL24571289 0.82 MEN1 (0.36) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL30296604 0.82 MEN1 (0.36) MAPTMEN1KMT2AL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 US disclosed
EP-4419203-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-08-28 EP disclosed
CN-118451080-A Tricyclic GPR65 modulators 帕蒂奥斯治疗有限公司 2024-08-06 CN disclosed
WO-2023067322-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 MAPT 4580/4885MEN1 4599/4885KMT2A 3316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.